Argos Therapeutics, which is developing immunotherapies for the treatment of cancer and HIV, announced terms for its IPO on Tuesday. The Durham, NC-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Argos Therapeutics would command a fully diluted market value of $247 million.
Argos Therapeutics, which was founded in 1997 and booked $5 million in sales for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol ARGS. Argos Therapeutics initially filed confidentially on November 12, 2013. Piper Jaffray, Stifel and JMP Securities are the joint bookrunners on the deal.
